SILENCE THERAPEUTICS PLC-ADR (SLN) Stock News

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Earnings Scheduled For February 27, 2025

Mentions: SSP CLCO CVEO DCI ...

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024

Silence Therapeutics just reported results for the second quarter of 2024.

SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Silence Therapeutics (NASDAQ:SLN) just reported results for the second quarter ...

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

The 3 Best Gene Editing Stocks to Buy in August 2024

These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.

Mentions: ALNY CRSP

Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks

It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it.

Mentions: MS LI VKTX AZN ...

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Silence Therapeutics (NASDAQ:SLN) just reported results for the first quarter o...

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024

Silence Therapeutics just reported results for the first quarter of 2024.

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress